B7h6 antibody and use thereof
AssigneeHefei Tg Immunopharma Co., Ltd.
InventorsZhigang TIAN, Guoshuai CAO, Weihua XIAO, Rui SUN, Haoyu SUN
Life of this patent
Estimating the term…
Abstract
The present disclosure discloses a B7H6 antibody and use thereof. The antibody includes heavy chain CDR1, heavy chain CDR2 and heavy chain CDR3; and light chain CDR1, light chain CDR2 and light chain CDR3. The antibody of the present disclosure is capable of binding to B7H6, and promoting the binding of B7H6 to the NK cell activating receptor NKp30, with an anti-cancer function.
Claims20
An antibody capable of binding to B7H6 or antigen binding fragment thereof, wherein the antibody or antigen binding fragment thereof comprises a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2, and a light chain CDR3, wherein
- the heavy chain CDR1 comprises at least one amino acid sequence selected from the group consisting of an amino acid sequence as set forth in SEQ ID NO. 1, and SEQ ID NO. 7, and an amino acid sequence in conservative modification form thereof;
- the heavy chain CDR2 comprises at least one amino acid sequence selected from the group consisting of an amino acid sequence as set forth in SEQ ID NO. 2, and SEQ ID NO. 8, and an amino acid sequence in conservative modification form thereof;
- the heavy chain CDR3 comprises at least one amino acid sequence selected from the group consisting of an amino acid sequence as set forth in SEQ ID NO. 3, and SEQ ID NO. 9, and an amino acid sequence in conservative modification form thereof;
- the light chain CDR1 comprises at least one amino acid sequence selected from the group consisting of an amino acid sequence as set forth in SEQ ID NO. 4, and SEQ ID NO. 10, and an amino acid sequence in conservative modification form thereof;
- the light chain CDR2 comprises at least one amino acid sequence selected from the group consisting of an amino acid sequence as set forth in SEQ ID NO. 5, SEQ ID NO. 11, and an amino acid sequence in conservative modification form thereof;
- and
- the light chain CDR3 comprises at least one amino acid sequence selected from the group consisting of an amino acid sequence as set forth in SEQ ID NO. 6, SEQ ID NO. 12, and an amino acid sequence in conservative modification form thereof.
A medicament, comprising an antibody or antigen binding fragment thereof, wherein the antibody or antigen binding fragment thereof comprises a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2, and a light chain CDR3, wherein
- the heavy chain CDR1 comprises at least one amino acid sequence selected from the group consisting of an amino acid sequence as set forth in SEQ ID NO. 1, and SEQ ID NO. 7, and an amino acid sequence in conservative modification form thereof;
- the heavy chain CDR2 comprises at least one amino acid sequence selected from the group consisting of an amino acid sequence as set forth in SEQ ID NO. 2, and SEQ ID NO. 8, and an amino acid sequence in conservative modification form thereof;
- the heavy chain CDR3 comprises at least one amino acid sequence selected from the group consisting of an amino acid sequence as set forth in SEQ ID NO. 3, and SEQ ID NO. 9, and an amino acid sequence in conservative modification form thereof;
- the light chain CDR1 comprises at least one amino acid sequence selected from the group consisting of an amino acid sequence as set forth in SEQ ID NO. 4, and SEQ ID NO. 10, and an amino acid sequence in conservative modification form thereof;
- the light chain CDR2 comprises at least one amino acid sequence selected from the group consisting of an amino acid sequence as set forth in SEQ ID NO. 5, SEQ ID NO. 11, and an amino acid sequence in conservative modification form thereof;
- and
- the light chain CDR3 comprises at least one amino acid sequence selected from the group consisting of an amino acid sequence as set forth in SEQ ID NO. 6, SEQ ID NO. 12, and an amino acid sequence in conservative modification form thereof.
A method for treating and/or preventing a B7H6-mediated disease, comprising administering to a subject an antibody or antigen binding fragment thereof;
- wherein the antibody or antigen binding fragment thereof comprises a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2, and a light chain CDR3, wherein
- the heavy chain CDR1 comprises at least one amino acid sequence selected from the group consisting of an amino acid sequence as set forth in SEQ ID NO. 1, and SEQ ID NO. 7, and an amino acid sequence in conservative modification form thereof;
- the heavy chain CDR2 comprises at least one amino acid sequence selected from the group consisting of an amino acid sequence as set forth in SEQ ID NO. 2, and SEQ ID NO. 8, and an amino acid sequence in conservative modification form thereof;
- the heavy chain CDR3 comprises at least one amino acid sequence selected from the group consisting of an amino acid sequence as set forth in SEQ ID NO. 3, and SEQ ID NO. 9, and an amino acid sequence in conservative modification form thereof;
- the light chain CDR1 comprises at least one amino acid sequence selected from the group consisting of an amino acid sequence as set forth in SEQ ID NO. 4, and SEQ ID NO. 10, and an amino acid sequence in conservative modification form thereof;
- the light chain CDR2 comprises at least one amino acid sequence selected from the group consisting of an amino acid sequence as set forth in SEQ ID NO. 5, SEQ ID NO. 11, and an amino acid sequence in conservative modification form thereof;
- and
- the light chain CDR3 comprises at least one amino acid sequence selected from the group consisting of an amino acid sequence as set forth in SEQ ID NO. 6, SEQ ID NO. 12, and an amino acid sequence in conservative modification form thereof.
Dependencies are inferred from the claim text.